251 related articles for article (PubMed ID: 34063247)
1.
Huang ST; Chen Y; Chang WC; Chen HF; Lai HC; Lin YC; Wang WJ; Wang YC; Yang CS; Wang SC; Hung MC
Viruses; 2021 May; 13(5):. PubMed ID: 34063247
[TBL] [Abstract][Full Text] [Related]
2. The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner.
Yamamoto M; Kiso M; Sakai-Tagawa Y; Iwatsuki-Horimoto K; Imai M; Takeda M; Kinoshita N; Ohmagari N; Gohda J; Semba K; Matsuda Z; Kawaguchi Y; Kawaoka Y; Inoue JI
Viruses; 2020 Jun; 12(6):. PubMed ID: 32532094
[TBL] [Abstract][Full Text] [Related]
3. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K; Meyerholz DK; Bartlett JA; McCray PB
mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
[TBL] [Abstract][Full Text] [Related]
4. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2.
Matsuyama S; Nagata N; Shirato K; Kawase M; Takeda M; Taguchi F
J Virol; 2010 Dec; 84(24):12658-64. PubMed ID: 20926566
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Hoffmann M; Kleine-Weber H; Schroeder S; Krüger N; Herrler T; Erichsen S; Schiergens TS; Herrler G; Wu NH; Nitsche A; Müller MA; Drosten C; Pöhlmann S
Cell; 2020 Apr; 181(2):271-280.e8. PubMed ID: 32142651
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 and SARS-CoV Spike-Mediated Cell-Cell Fusion Differ in Their Requirements for Receptor Expression and Proteolytic Activation.
Hörnich BF; Großkopf AK; Schlagowski S; Tenbusch M; Kleine-Weber H; Neipel F; Stahl-Hennig C; Hahn AS
J Virol; 2021 Apr; 95(9):. PubMed ID: 33608407
[TBL] [Abstract][Full Text] [Related]
7. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
J Virol; 2021 Oct; 95(21):e0097521. PubMed ID: 34406858
[TBL] [Abstract][Full Text] [Related]
8. Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat.
Sun G; Sui Y; Zhou Y; Ya J; Yuan C; Jiang L; Huang M
J Virol; 2021 Sep; 95(19):e0086121. PubMed ID: 34160253
[TBL] [Abstract][Full Text] [Related]
9. TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein.
Heurich A; Hofmann-Winkler H; Gierer S; Liepold T; Jahn O; Pöhlmann S
J Virol; 2014 Jan; 88(2):1293-307. PubMed ID: 24227843
[TBL] [Abstract][Full Text] [Related]
10. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.
Hoffmann M; Hofmann-Winkler H; Smith JC; Krüger N; Arora P; Sørensen LK; Søgaard OS; Hasselstrøm JB; Winkler M; Hempel T; Raich L; Olsson S; Danov O; Jonigk D; Yamazoe T; Yamatsuta K; Mizuno H; Ludwig S; Noé F; Kjolby M; Braun A; Sheltzer JM; Pöhlmann S
EBioMedicine; 2021 Mar; 65():103255. PubMed ID: 33676899
[TBL] [Abstract][Full Text] [Related]
11. Molecular Interactions of Tannic Acid with Proteins Associated with SARS-CoV-2 Infectivity.
Haddad M; Gaudreault R; Sasseville G; Nguyen PT; Wiebe H; Van De Ven T; Bourgault S; Mousseau N; Ramassamy C
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269785
[TBL] [Abstract][Full Text] [Related]
12. A high-throughput screen for TMPRSS2 expression identifies FDA-approved compounds that can limit SARS-CoV-2 entry.
Chen Y; Lear TB; Evankovich JW; Larsen MB; Lin B; Alfaras I; Kennerdell JR; Salminen L; Camarco DP; Lockwood KC; Tuncer F; Liu J; Myerburg MM; McDyer JF; Liu Y; Finkel T; Chen BB
Nat Commun; 2021 Jun; 12(1):3907. PubMed ID: 34162861
[TBL] [Abstract][Full Text] [Related]
13. Single-cell analysis of SARS-CoV-2 receptor ACE2 and spike protein priming expression of proteases in the human heart.
Liu H; Gai S; Wang X; Zeng J; Sun C; Zhao Y; Zheng Z
Cardiovasc Res; 2020 Aug; 116(10):1733-1741. PubMed ID: 32638018
[TBL] [Abstract][Full Text] [Related]
14. TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection.
Iwata-Yoshikawa N; Okamura T; Shimizu Y; Hasegawa H; Takeda M; Nagata N
J Virol; 2019 Mar; 93(6):. PubMed ID: 30626688
[TBL] [Abstract][Full Text] [Related]
15. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
[TBL] [Abstract][Full Text] [Related]
16. Metadichol®: A Novel Nanolipid Formulation That Inhibits SARS-CoV-2 and a Multitude of Pathological Viruses In Vitro.
Raghavan PR
Biomed Res Int; 2022; 2022():1558860. PubMed ID: 35039793
[TBL] [Abstract][Full Text] [Related]
17. Targeting the intestinal TMPRSS2 protease to prevent SARS-CoV-2 entry into enterocytes-prospects and challenges.
Mahmoud IS; Jarrar YB
Mol Biol Rep; 2021 May; 48(5):4667-4675. PubMed ID: 34023987
[TBL] [Abstract][Full Text] [Related]
18. Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19.
Choudhary S; Silakari O
Virus Res; 2020 Nov; 289():198146. PubMed ID: 32866534
[TBL] [Abstract][Full Text] [Related]
19. Hesperidin Is a Potential Inhibitor against SARS-CoV-2 Infection.
Cheng FJ; Huynh TK; Yang CS; Hu DW; Shen YC; Tu CY; Wu YC; Tang CH; Huang WC; Chen Y; Ho CY
Nutrients; 2021 Aug; 13(8):. PubMed ID: 34444960
[TBL] [Abstract][Full Text] [Related]
20.
Liu H; Ye F; Sun Q; Liang H; Li C; Li S; Lu R; Huang B; Tan W; Lai L
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):497-503. PubMed ID: 33491508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]